We are focused on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need.

Our technology

The unique potential of Radiopharmaceuticals in treating oncological diseases.

Learn more

Our pipeline

The unique potential of being First to Market or Best in Class.

Learn more

Our team

We have a unique commitment to improve patients’ hope in fighting cancer.

Learn more

Information for investors

Stock price, Company governance & updates from our multiple development programs.

Learn more

Latest news

Media Coverage

September 15, 2023

RAD Announces Clinical Data Presentation for 68Ga-Trivehexin (RAD 301), at 2023 EANM Annual Meeting

Read moreRead more

ASX Releases

August 24, 2023

TerThera Terbium-161 isotope supply agreement expanded

Read moreRead more

ASX Releases

August 18, 2023

EGM Presentation

Read moreRead more